Lipoxin A4
Based on 2 publication(s) in Google Scholar
Lipoxin A4 (LXA4), an endogenous lipoxygenase-derived eicosanoid mediator, has potent dual pro-resolving and anti-inflammatory properties. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes (NHEKs) associated with the ERK1/2 and NF-kB pathways. Lipoxin A4 inhibits serum amyloid A (SAA)-mediated IL-8 release with an IC50 value of 25.74 nM.
The product specifications provided below refer solely to the active content of Lipoxin A4.
For research use only. We do not sell to patients.
- Purity : 98.0%
- CAS No.: 89663-86-5
- Formula: C20H32O5
- Molecular Weight:352.47
-
Storage:Shipping with dry ice
Solution, -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-125527
Resolvin D1Endogenous Inflammation Mediator -
HY-P1119
WRW4FPRL1 Antagonist -
HY-116953
Lipoxin B4Anti-inflammatory Agent -
HY-125527A
17(R)-Resolvin D1TRPV3 Inhibitor -
HY-P1120
WKYMVmN-Formyl Peptide Receptor Agonist -
HY-113509B
15(R)-Lipoxin A4Specialized Pro-resolving Mediator -
HY-P9917
TocilizumabIL-6R Neutralizing Antibody -
HY-130413
Protectin D1Neuroprotectin D1 -
HY-119684
Maresin 2Anti-inflammatory And Pro-resolving Mediator -
HY-125516
MCTR3Pro-resolving Mediator -
HY-115381
Lipoxin A5Endogenous Metabolite -
HY-126722
Lipoxin A4 methyl esterLipoxin Analog
Publications Citing Use of MedChemExpress (MCE) Lipoxin A4
MoreAll Endogenous Metabolite Isoforms
More
Biological Activity
Description
The product specifications provided below refer solely to the active content of Lipoxin A4.
IC50 & Target
|
IL-6 |
IL-8 |
Human Endogenous Metabolite |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| THP-1 | EC50 |
5 nM
Compound: 1
|
Induction of phagocytosis in human THP-1-MF0 macrophages pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
Induction of phagocytosis in human THP-1-MF0 macrophages pretreated for 30 mins followed by fluorescently labeled Escherichia coli derived bio-particles addition and measured after 2 hrs
|
[PMID: 34138563] |
| THP-1 | IC50 |
1 pM
Compound: 1
|
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IFNgamma release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IFNgamma release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
|
[PMID: 34138563] |
| THP-1 | IC50 |
1 pM
Compound: 1
|
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-1beta release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-1beta release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
|
[PMID: 34138563] |
| THP-1 | IC50 |
1 pM
Compound: 1
|
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-6 release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
Anti-inflammatory activity against human THP-1 monocytes assessed as reduction in LPS-induced IL-6 release pretreated for 30 mins followed LPS stimulation and measured after 24 hrs by multiplex chemiluminescence detection method
|
[PMID: 34138563] |
In Vitro
LXA4 pretreatment (100 nM for 30 minutes) downregulates the LPS-induced secretion and expression of HMGB1 in keratinocytes[1].
Lipoxin A4 (LXA4) inhibits the expression of IL-6 and IL-8 in NHEKs[2].
Lipoxin A4 downregulates the expression of cyclin D1[2].
Lipoxin A4 also suppresses the ERK1/2 phosphorylation and NF-kB-p65 nuclear translocation of NHEKs[2].
LXA4 (100 nM; preincubation for 30 minutes)inhibits the proliferation of NHEKs with or without stimulating by LPS (10 μg/mL)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Normal human epidermal keratinocytes (NHEKs)
-
Concentration:100 nM
-
Incubation Time:30 minutes.
-
Result:HMGB1 protein levels in the cytoplasm of NHEKs were induced by LPS, which were decreased after preincubation with LXA4 but decreased in the nucleus after stimulation with LPS.
-
Cell Line:Normal human epidermal keratinocytes (NHEKs)
-
Concentration:100 nM
-
Incubation Time:30 minutes
-
Result:A significant increase in proliferation of NHEKs after 7 days of stimulation with LPS (10 μg/mL) was seen. However, there was a significant decrease in the proliferation of NHEKs when pretreated with LXA4 for 30 min.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rat models of non-compressive lumbar disc herniation[4]
-
Dosage:10 and 100 ng
-
Administration:Intrathecal injection; 3 days
-
Result:Alleviated the development of neuropathic pain.
Inhibited the upregulation of pro-inflammatory cytokines (TNF-a and IL-1β).
Upregulated the expression of anti-inflammatory cytokines (TGF-β1 and IL-10) and attenuated the activation of NF-κB/p65, p-ERK, p-JNK, but not p-p38.
Chemical Information
-
CAS No. 89663-86-5
-
Appearance Liquid
-
Molecular Weight 352.47
-
Formula C20H32O5
-
Color Colorless to light yellow
-
SMILES
CCCCC[C@H](O)/C=C/C=C\C=C\C=C\[C@@H](O)[C@@H](O)CCCC(O)=O
-
Synonyms
LXA4
-
Structure Classification
-
Initial Source
-
Shipping
Shipping with dry ice.
-
Storage
Solution, -20°C, 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Inflamm Res
Lipoxin A4 Attenuates E. coli-Induced ARDS-Like Lung Injury in Mice via ALX/FPR2-Dependent Macrophage Reprogramming. [Abstract]2026 Jul 16:19:597266. PMID: 42518610 -
Drug Alcohol Depend
The effect of the NLRP1 inflammasome on methamphetamine-induced cognitive impairment in rats. [Abstract]2022 Aug 1:237:109537. PMID: 35752024
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (544 KB)
- English - EN (544 KB)
- Français - FR (544 KB)
- Deutsch - DE (544 KB)
- Norwegian - NO (544 KB)
- Español - ES (544 KB)
- Swedish - SV (544 KB)
- Italian - IT (544 KB)
- Korean - KR (544 KB)
- Portuguese - PT (544 KB)
-
Handling Instructions (2659 KB)
References
[1]. Feng Hu, et al. Lipoxin A4 inhibits proliferation and inflammatory cytokine/chemokine production of human epidermal keratinocytes associated with the ERK1/2 and NF-κB pathways. J Dermatol Sci. 2015 Jun;78(3):181-8. [Content Brief]
[2]. Steven Bozinovski, et al. Serum amyloid A opposes lipoxin A₄ to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc Natl Acad Sci U S A. 2012 Jan 17;109(3):935-40. [Content Brief]
[3]. Xinxin Liu, et al. Lipoxin A4 and its analog suppress inflammation by modulating HMGB1 translocation and expression in psoriasis.Sci Rep. 2017 Aug 2;7(1):7100. [Content Brief]
[4]. Miao GS, et al. Lipoxin A4 attenuates radicular pain possibly by inhibiting spinal ERK, JNK and NF-κB/p65 and cytokine signals, but not p38, in a rat model of non-compressive lumbar disc herniation. Neuroscience. 2015 Aug 6;300:10-8. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Lipoxin A4 Related Classifications
HY-113509 Related Classifications
Powered by Bioz